CA2698203C - Anticorps anti-cxcr5 humanises, leurs derives et leurs utilisations - Google Patents
Anticorps anti-cxcr5 humanises, leurs derives et leurs utilisations Download PDFInfo
- Publication number
- CA2698203C CA2698203C CA2698203A CA2698203A CA2698203C CA 2698203 C CA2698203 C CA 2698203C CA 2698203 A CA2698203 A CA 2698203A CA 2698203 A CA2698203 A CA 2698203A CA 2698203 C CA2698203 C CA 2698203C
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- cxcr5
- cells
- antibodies
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Physiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medical Informatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
Abstract
La présente invention porte sur des anticorps humanisés qui se lient spécifiquement à CXCR5 et qui peuvent, par exemple, inhiber la fonction CXCR5. L'invention inclut également des utilisations des anticorps pour traiter ou prévenir des maladies ou des troubles liés à CXCR5.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96879207P | 2007-08-29 | 2007-08-29 | |
US60/968,792 | 2007-08-29 | ||
PCT/US2008/074381 WO2009032661A1 (fr) | 2007-08-29 | 2008-08-27 | Anticorps anti-cxcr5 humanisés, leurs dérivés et leurs utilisations |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2698203A1 CA2698203A1 (fr) | 2009-03-12 |
CA2698203C true CA2698203C (fr) | 2018-09-11 |
Family
ID=40429297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2698203A Active CA2698203C (fr) | 2007-08-29 | 2008-08-27 | Anticorps anti-cxcr5 humanises, leurs derives et leurs utilisations |
Country Status (44)
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120263733A1 (en) * | 2002-11-15 | 2012-10-18 | Morehouse School Of Medicine | Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation |
AU2007274738B2 (en) | 2006-07-18 | 2013-11-28 | Sanofi-Aventis | Antagonist antibody against EphA2 for the treatment of cancer |
UA117446C2 (uk) | 2007-08-29 | 2018-08-10 | Санофі-Авентіс | Гуманізоване антитіло до cxcr5 |
WO2010019493A1 (fr) * | 2008-08-14 | 2010-02-18 | Merck Sharp & Dohme Corp. | Procédés de purification d'anticorps à l'aide d'une chromatographie d'affinité sur protéine a |
FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
UY32914A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Anticuerpos que se usan específicamente al receptor epha2 |
MX350206B (es) * | 2009-11-30 | 2017-08-28 | Biotest Ag | Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle). |
EP2402371A1 (fr) | 2010-07-01 | 2012-01-04 | Sanofi | Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations |
EP2336188A1 (fr) | 2009-12-18 | 2011-06-22 | Sanofi-Aventis | Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations |
EP2513147B1 (fr) | 2009-12-18 | 2016-07-20 | Sanofi | Nouveaux anticorps antagonistes et leurs fragments fab dirigés contre gpvi, et utilisations de ceux-ci |
EP2397495A1 (fr) | 2010-06-21 | 2011-12-21 | Sanofi | Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations |
FR2958936A1 (fr) | 2010-04-14 | 2011-10-21 | Sanofi Aventis | Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs |
WO2012010582A1 (fr) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anticorps anti-cxcr5 et leurs méthodes d'utilisation |
UY33578A (es) | 2010-08-31 | 2012-03-30 | Sanofi Sa | PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS |
UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
WO2012082494A2 (fr) * | 2010-12-14 | 2012-06-21 | Morehouse School Of Medicine | Utilisation d'anticorps anti-cxcl13 et anti-cxcr5 pour le traitement ou la détection du cancer |
AR085302A1 (es) | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
ES2698606T3 (es) | 2012-01-20 | 2019-02-05 | Genzyme Corp | Anticuerpos anti-CXCR3 |
ES2702246T3 (es) * | 2012-03-26 | 2019-02-28 | Sanofi Sa | Formulaciones de agente de unión IgG4 estables |
BR122019026701B1 (pt) * | 2012-03-26 | 2023-01-24 | Sanofi | Formulações de agentes de ligação à base de igg4 estáveis, kit, e dispositivo ou recipiente pré-cheios |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
KR102166083B1 (ko) | 2012-03-28 | 2020-10-16 | 사노피 | 브라디키닌 b1 수용체 리간드에 대한 항체 |
CN107478843A (zh) * | 2012-06-27 | 2017-12-15 | 吉安特科技公司 | 用于炎性疾病的抗‑cxcl9、抗‑cxcl10、抗‑cxcl11、抗‑cxcl13、抗‑cxcr3和抗‑cxcr5试剂 |
WO2014003742A1 (fr) * | 2012-06-27 | 2014-01-03 | Morehouse School Of Medicine | Agents anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 et anti-cxcr5 pour l'inhibition de l'inflammation |
RS60043B1 (sr) | 2012-11-20 | 2020-04-30 | Sanofi Sa | Anti-ceacam5 antitela i njihova primena |
EP2925779A1 (fr) | 2012-11-30 | 2015-10-07 | Institut Pasteur | Utilisation d'anticorps anti-fcyri et/ou anti-fcyriia pour traiter une arthrite, une inflammation, une thrombopénie et un choc anaphylactique |
US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
ES2871816T3 (es) | 2012-12-27 | 2021-11-02 | Sanofi Sa | Anticuerpos anti-LAMP1 y conjugados anticuerpo-fármaco, y usos de los mismos |
JO3580B1 (ar) * | 2013-03-15 | 2020-07-05 | Lilly Co Eli | أجسام مضادة لكيموكين elr+ cxc شامل |
SG11201508502RA (en) * | 2013-05-02 | 2015-11-27 | Ares Trading Sa | Monoclonal antibody directed against cxcr5 |
EP3013361B1 (fr) * | 2013-06-24 | 2021-10-06 | NexImmune, Inc. | Compositions et procédés pour immunothérapie |
TW201734054A (zh) | 2013-08-13 | 2017-10-01 | 賽諾菲公司 | 胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途 |
BR112016002753A2 (pt) | 2013-08-13 | 2017-11-21 | Sanofi Sa | anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos |
EP3119194B1 (fr) * | 2014-03-21 | 2021-04-28 | Regeneron Pharmaceuticals, Inc. | Animaux non humains qui produisent des protéines de liaison monodomaine |
CA2958674A1 (fr) * | 2014-08-22 | 2016-02-25 | Sorrento Therapeutics, Inc. | Proteines de liaison a l'antigene se liant a wisp5 |
EP3237003B1 (fr) * | 2014-12-24 | 2021-08-11 | NexImmune, Inc | Compositions de nanoparticules et méthodes pour l'immunothérapie |
EP3247725B1 (fr) | 2015-01-23 | 2020-07-01 | Sanofi | Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement au cd3 et/ou cd123 |
MX2017017138A (es) | 2015-06-23 | 2018-04-30 | Bayer Pharma AG | Conjugados homogeneos especificos de sitio con inhibidores de ksp. |
CA3003759A1 (fr) | 2015-11-03 | 2017-05-11 | Merck Patent Gmbh | Anticorps bispecifiques pour une plus grande selectivite et une meilleure inhibition des tumeurs, et utilisations associees |
CN106674352B (zh) * | 2015-11-10 | 2020-05-15 | 孙嘉琳 | 抗肿瘤蛋白内皮抑素的衍生物及应用 |
SG11201808167VA (en) | 2016-03-24 | 2018-10-30 | Bayer Pharma AG | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
JP7022707B2 (ja) | 2016-06-15 | 2022-02-18 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ksp阻害剤および抗cd123抗体を含む特異的抗体-薬物-コンジュゲート(adc) |
TWI760345B (zh) | 2016-07-05 | 2022-04-11 | 法商賽諾菲公司 | 抗體調配物 |
EP3481420A1 (fr) * | 2016-07-05 | 2019-05-15 | Sanofi | Formule d'anticorps. |
TWI790206B (zh) | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至cd3和cd123的雙特異性抗體樣結合蛋白 |
KR102628772B1 (ko) * | 2016-09-26 | 2024-01-24 | 엠피오, 아이엔씨. | 난자, 수정란 또는 배아의 질 개선제 |
KR20190099250A (ko) | 2016-12-21 | 2019-08-26 | 바이엘 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물 |
CA3047522A1 (fr) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Conjugues anticorps-principe actif (adc) specifiques renfermant des inhibiteurs de ksp |
MX2019007641A (es) | 2016-12-21 | 2019-09-09 | Bayer Pharma AG | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente. |
WO2018119288A1 (fr) | 2016-12-22 | 2018-06-28 | Sanofi | Anticorps anti-cxcr3 humains pour le traitement du vitiligo |
JP2020504744A (ja) | 2016-12-22 | 2020-02-13 | サノフイSanofi | 枯渇活性を有するヒト化cxcr3抗体およびその使用方法 |
EP3354278A1 (fr) | 2017-01-31 | 2018-08-01 | Sanofi | Effet de protection des cellules neuronales d'anticorps spécifiques de la forme protofibrillaire du peptide bêta-amyloïde |
TWI808963B (zh) * | 2017-03-22 | 2023-07-21 | 法商賽諾菲公司 | 使用人類化抗cxcr5抗體治療狼瘡 |
AU2018238540A1 (en) * | 2017-03-22 | 2019-11-07 | Sanofi | Treatment of lupus using humanized anti-CXCR5 antibodies |
EP3630182A4 (fr) * | 2017-05-24 | 2021-02-24 | Development Center for Biotechnology | Anticorps humanisés anti-globo h et leurs utilisations dans des traitements du cancer |
CA3064966A1 (fr) | 2017-06-30 | 2019-01-03 | Zymeworks Inc. | Fabs chimeriques stabilises |
EP3717516A1 (fr) * | 2017-12-01 | 2020-10-07 | Pfizer Inc | Anticorps anti-cxcr5, compositions les contenant et leurs utilisations |
EP3746079A1 (fr) | 2018-01-31 | 2020-12-09 | Bayer Aktiengesellschaft | Conjugués anticorps-médicament (adc) avec des inhibiteurs de nampt |
US20210002366A1 (en) * | 2018-02-13 | 2021-01-07 | Indian Institute Of Technology Bombay | Novel humanized anti-cd19 chimeric antigen receptor, its nucelic acid sequence and its preparation |
US11576984B2 (en) * | 2018-03-26 | 2023-02-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of using |
BR112020025718A2 (pt) * | 2018-06-18 | 2021-04-06 | Bayer Aktiengesellschaft | Conjugados de ligante/agente ativo direcionados contra cxcr5, tendo aglutinantes enzimaticamente cliváveis e perfil de atividade melhorado |
EP3753954A1 (fr) | 2019-06-21 | 2020-12-23 | Université de Franche-Comté | Anticorps anti-cd123, récepteurs d'antigène chimériques anti-cd123 et lymphocytes t de récepteurs d'antigène chimériques anti-cd123 |
US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
US20230132241A1 (en) | 2020-01-15 | 2023-04-27 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
CA3169521A1 (fr) | 2020-02-28 | 2021-09-02 | Marie-Priscille Brun | Polypeptides de liaison modifies pour conjugaison optimisee de medicament |
WO2023010483A1 (fr) * | 2021-08-05 | 2023-02-09 | Hifibio (Hk) Limited | Anticorps anti-cxcr5 humain et ses utilisations |
WO2021214227A1 (fr) | 2020-04-24 | 2021-10-28 | Sanofi | Combinaisons antitumorales contenant des conjugués anticorps anti-ceacam5 et du cétuximab |
MX2022013402A (es) | 2020-04-24 | 2022-11-14 | Sanofi Sa | Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5 y folfiri. |
WO2021214223A1 (fr) | 2020-04-24 | 2021-10-28 | Sanofi | Combinaisons antitumorales contenant des conjugués d'anticorps anti-ceacam5 et du folfox |
CA3181002A1 (fr) | 2020-04-24 | 2021-10-28 | Sanofi | Combinaisons antitumorales contenant des conjugues anticorps anti-ceacam5, de la trifluridine et du tipiracil |
US20240010749A1 (en) | 2020-09-04 | 2024-01-11 | Merck Patent Gmbh | Anti-ceacam5 antibodies and conjugates and uses thereof |
CN112521499B (zh) * | 2020-12-24 | 2022-10-25 | 四川大学 | 抗cxcl13抗体及其用途 |
MX2023009100A (es) | 2021-02-03 | 2023-09-25 | Mozart Therapeutics Inc | Agentes aglutinantes y métodos para usar los mismos. |
EP4305073A1 (fr) * | 2021-03-09 | 2024-01-17 | HiFiBiO (HK) Limited | Anticorps anti-cxcr5 humain et ses utilisations |
EP4337699A1 (fr) * | 2021-05-12 | 2024-03-20 | Biolegend, Inc. | Anticorps anti-ccr8, fragments de liaison à l'antigène de ceux-ci, et agents et compositions et leurs procédés de fabrication et d'utilisation |
CN113278072B (zh) * | 2021-05-25 | 2023-06-20 | 河南凯普瑞生物技术有限公司 | 一种抗体的制备方法 |
WO2023051656A1 (fr) * | 2021-09-30 | 2023-04-06 | 贝达药业股份有限公司 | Anticorps bispécifique et son application |
WO2023076876A1 (fr) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation de réponses immunitaires à des vecteurs viraux |
WO2023079057A1 (fr) | 2021-11-05 | 2023-05-11 | Sanofi | Combinaisons antitumorales contenant des conjugués anticorps-médicament anti-ceacam5 et des anticorps anti-vegfr-2 |
WO2023172968A1 (fr) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Anticorps anti-gd2, immunoconjugués et leurs utilisations thérapeutiques |
TW202346354A (zh) | 2022-03-09 | 2023-12-01 | 德商馬克專利公司 | 抗ceacam5抗體及其結合物及用途 |
WO2023212587A1 (fr) | 2022-04-28 | 2023-11-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Polypeptides recombinants comprenant des anticorps à domaine unique ciblant herv-k sous-type hml-2 |
WO2024011077A2 (fr) | 2022-07-04 | 2024-01-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Anticorps monoclonaux dirigés contre psd95 phosphorylée et leurs utilisations |
CN117004700A (zh) * | 2023-10-07 | 2023-11-07 | 北京爱博生生物技术有限公司 | 单克隆抗体可变区基因高通量测序的方法及其所用组合物与试剂盒 |
Family Cites Families (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (fr) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotique C-15003 PHO et sa préparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
WO1982001188A1 (fr) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | Composes 4,5-deoxymaytansinoide et leur procede de preparation |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
WO1986005807A1 (fr) | 1985-04-01 | 1986-10-09 | Celltech Limited | Lignee cellulaire de myelomes transformee et procede d'expression d'un gene codant un polypeptide eucaryotque employant cette lignee |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
EP0206448B1 (fr) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hémoglobine liée à un poly(oxyde d'alkylène) |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
WO1987005330A1 (fr) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Procede pour ameliorer la stabilite des glycoproteines |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
KR900700134A (ko) | 1988-04-15 | 1990-08-11 | 원본미기재 | Il-2 수용체-특이적 키메릭 항체 |
JP3105898B2 (ja) | 1988-04-16 | 2000-11-06 | セルテック リミテッド | 組換えdnaタンパクの製造方法 |
AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
US5534617A (en) | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
WO1990005144A1 (fr) | 1988-11-11 | 1990-05-17 | Medical Research Council | Ligands a domaine unique, recepteurs comprenant lesdits ligands, procedes pour leur production, et emploi desdits ligands et recepteurs |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
CA2018228C (fr) | 1989-06-05 | 1996-02-27 | Nancy L. Parenteau | Systemes et milieu de culture cellulaire |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
WO1991014438A1 (fr) | 1990-03-20 | 1991-10-03 | The Trustees Of Columbia University In The City Of New York | Anticorps chimeriques utilisant des ligands de liaison de recepteurs a la place de leur region constante |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
JPH07500961A (ja) | 1990-10-01 | 1995-02-02 | ユニバーシティ オブ コネチカット | 細胞による選択的内在化を目的としたウイルス及び細胞の標的設定 |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
ATE218889T1 (de) | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
WO1992020316A2 (fr) | 1991-05-14 | 1992-11-26 | University Of Connecticut | Apport cible de genes codant des proteines immunogenes |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
ES2149774T3 (es) | 1991-06-05 | 2000-11-16 | Univ Connecticut | Aportacion dirigida de genes que codifican proteinas secretoras. |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
WO1993008829A1 (fr) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions induisant la destruction de cellules infectees par l'hiv |
PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
WO1993014188A1 (fr) | 1992-01-17 | 1993-07-22 | The Regents Of The University Of Michigan | Virus cible |
FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
CA2076465C (fr) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Conjugues agents de liaison cellulaire d'analogues et de derives de cc-1065 |
EP0633943A4 (fr) | 1992-04-03 | 1997-05-02 | Alexander T Young | Therapie genique utilisant des vecteurs viraux cibles. |
WO1993021319A1 (fr) | 1992-04-08 | 1993-10-28 | Cetus Oncology Corporation | ANTICORPS HUMANISES SPECIFIES PAR C-erbB-2 |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
JPH08501085A (ja) | 1992-08-26 | 1996-02-06 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 抗腫瘍剤としてのサイトカインip−10の利用 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
CA2146747C (fr) | 1992-10-09 | 2006-12-19 | Brian A. Naughton | Cellules souches du foie |
CA2592997A1 (fr) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Vecteurs pseudo-adenoviraux |
US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
KR100654645B1 (ko) | 1995-04-27 | 2007-04-04 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
CA2219486A1 (fr) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Anticorps humains derives de xeno-souris immunisees |
EP0850313B8 (fr) | 1995-09-08 | 2009-07-29 | Genzyme Corporation | Vecteurs aav ameliores pour la therapie genique |
AU5711196A (en) | 1996-03-14 | 1997-10-01 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
WO1997034631A1 (fr) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Domaines analogues a l'immunoglobuline a demi-vies prolongees |
CN1107072C (zh) | 1996-03-22 | 2003-04-30 | 人类基因组科学公司 | 编程性细胞死亡诱导分子ⅱ |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
WO1998023289A1 (fr) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | Modulation de la fixation de l'igg au fcrn |
KR20080059467A (ko) | 1996-12-03 | 2008-06-27 | 아브게닉스, 인크. | 복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체 |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
KR100663319B1 (ko) | 1997-04-14 | 2007-01-02 | 마이크로메트 에이지 | 인간 17-1에이항원에 대해 특이성을 갖는 인간항체 및 그용도 |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6642051B1 (en) | 1997-10-21 | 2003-11-04 | Targeted Genetics Corporation | Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors |
WO1999023105A1 (fr) | 1997-11-03 | 1999-05-14 | Human Genome Sciences, Inc. | Vegi, un inhibiteur de l'angiogenese et de la croissance tumorale |
AU770952B2 (en) | 1999-03-01 | 2004-03-11 | Genentech Inc. | Antibodies for cancer therapy and diagnosis |
CA2405709A1 (fr) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Proteines fusionnees a l'albumine |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
PL366062A1 (en) * | 2000-09-08 | 2005-01-24 | Micromet Ag | Antibody and/or chemokine constructs and their use in immunological disorders |
US7321026B2 (en) * | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
IL161784A0 (en) * | 2001-12-21 | 2005-11-20 | Anormed Inc | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US7470775B2 (en) * | 2002-06-07 | 2008-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-CD30 stalk and anti-CD30 antibodies suitable for use in immunotoxins |
AU2003251471A1 (en) * | 2002-08-06 | 2004-02-25 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5) |
TW200530269A (en) * | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
AU2005249490B2 (en) | 2004-06-01 | 2010-07-29 | Genentech, Inc. | Antibody drug conjugates and methods |
US20060148009A1 (en) | 2004-10-12 | 2006-07-06 | Xencor, Inc. | Prediction and assessment of immunogenicity |
GB0607774D0 (en) | 2006-04-20 | 2006-05-31 | Renovo Group Plc | Medicaments |
TW200813086A (en) | 2006-05-11 | 2008-03-16 | Hoffmann La Roche | Immunereconstituted mouse |
UA117446C2 (uk) | 2007-08-29 | 2018-08-10 | Санофі-Авентіс | Гуманізоване антитіло до cxcr5 |
-
2008
- 2008-08-27 UA UAA201312423A patent/UA117446C2/uk unknown
- 2008-08-27 BR BRPI0815983A patent/BRPI0815983A2/pt not_active Application Discontinuation
- 2008-08-27 CN CN201410307133.3A patent/CN104017078B/zh active Active
- 2008-08-27 SI SI200831964T patent/SI2195023T1/en unknown
- 2008-08-27 KR KR1020147023916A patent/KR20140117638A/ko not_active Application Discontinuation
- 2008-08-27 MX MX2013005976A patent/MX338395B/es unknown
- 2008-08-27 HU HUE08798744A patent/HUE037489T2/hu unknown
- 2008-08-27 TR TR2018/07983T patent/TR201807983T4/tr unknown
- 2008-08-27 DK DK08798744.2T patent/DK2195023T3/en active
- 2008-08-27 NO NO08798744A patent/NO2195023T3/no unknown
- 2008-08-27 PL PL08798744T patent/PL2195023T3/pl unknown
- 2008-08-27 KR KR1020147026311A patent/KR101667944B1/ko active IP Right Grant
- 2008-08-27 EP EP20191628.5A patent/EP3792284A1/fr active Pending
- 2008-08-27 EP EP08798744.2A patent/EP2195023B1/fr active Active
- 2008-08-27 MX MX2013014467A patent/MX346172B/es unknown
- 2008-08-27 CA CA2698203A patent/CA2698203C/fr active Active
- 2008-08-27 KR KR1020157017528A patent/KR101701140B1/ko active IP Right Grant
- 2008-08-27 RU RU2015147300A patent/RU2015147300A/ru not_active Application Discontinuation
- 2008-08-27 KR KR1020107006630A patent/KR101599704B1/ko active IP Right Grant
- 2008-08-27 EP EP18154804.1A patent/EP3354662B1/fr active Active
- 2008-08-27 PT PT87987442T patent/PT2195023T/pt unknown
- 2008-08-27 UY UY31309A patent/UY31309A1/es not_active Application Discontinuation
- 2008-08-27 MX MX2013014465A patent/MX338397B/es unknown
- 2008-08-27 UA UAA201003491A patent/UA104715C2/uk unknown
- 2008-08-27 PE PE2008001444A patent/PE20090993A1/es not_active Application Discontinuation
- 2008-08-27 RS RS20180659A patent/RS57273B1/sr unknown
- 2008-08-27 MX MX2013014466A patent/MX338474B/es unknown
- 2008-08-27 CN CN201410307453.9A patent/CN104017079B/zh active Active
- 2008-08-27 NZ NZ583605A patent/NZ583605A/xx not_active IP Right Cessation
- 2008-08-27 WO PCT/US2008/074381 patent/WO2009032661A1/fr active Application Filing
- 2008-08-27 RU RU2010111751/10A patent/RU2571515C2/ru not_active IP Right Cessation
- 2008-08-27 MX MX2010001975A patent/MX2010001975A/es active IP Right Grant
- 2008-08-27 AU AU2008296538A patent/AU2008296538B2/en active Active
- 2008-08-27 PA PA20088794201A patent/PA8794201A1/es unknown
- 2008-08-27 LT LTEP08798744.2T patent/LT2195023T/lt unknown
- 2008-08-27 SG SG10201407388XA patent/SG10201407388XA/en unknown
- 2008-08-27 US US12/675,799 patent/US8647622B2/en active Active
- 2008-08-27 MY MYPI2010000837A patent/MY159201A/en unknown
- 2008-08-27 ES ES08798744.2T patent/ES2672769T3/es active Active
- 2008-08-27 CN CN202010815880.3A patent/CN111909273B/zh active Active
- 2008-08-27 CN CN200880113572.3A patent/CN101842115B/zh active Active
- 2008-08-27 JP JP2010523100A patent/JP5743543B2/ja active Active
- 2008-08-29 TW TW097133372A patent/TWI439468B/zh not_active IP Right Cessation
- 2008-08-29 TW TW105114943A patent/TWI608017B/zh not_active IP Right Cessation
- 2008-08-29 CL CL2008002565A patent/CL2008002565A1/es unknown
- 2008-08-29 TW TW103111438A patent/TWI574976B/zh not_active IP Right Cessation
- 2008-08-29 AR ARP080103776A patent/AR068354A1/es not_active Application Discontinuation
- 2008-08-29 TW TW106127131A patent/TW201741341A/zh unknown
-
2010
- 2010-02-19 NI NI201000028A patent/NI201000028A/es unknown
- 2010-02-19 NI NI2010000281A patent/NI201000281A/es unknown
- 2010-02-23 TN TNP2010000092A patent/TN2010000092A1/fr unknown
- 2010-02-23 EC EC2010009985A patent/ECSP109985A/es unknown
- 2010-02-23 CR CR11293A patent/CR11293A/es unknown
- 2010-02-24 SV SV2010003494A patent/SV2010003494A/es unknown
- 2010-02-25 IL IL204173A patent/IL204173A/en active IP Right Grant
- 2010-02-26 DO DO2010000069A patent/DOP2010000069A/es unknown
- 2010-03-02 ZA ZA2010/01514A patent/ZA201001514B/en unknown
- 2010-03-08 MA MA32673A patent/MA31821B1/fr unknown
- 2010-04-05 CO CO10037770A patent/CO6270238A2/es active IP Right Grant
-
2013
- 2013-03-11 US US13/794,244 patent/US9243067B2/en active Active
- 2013-03-11 US US13/794,253 patent/US20130243793A1/en not_active Abandoned
- 2013-03-11 US US13/794,264 patent/US8980262B2/en active Active
- 2013-03-11 US US13/794,281 patent/US9175087B2/en active Active
- 2013-03-11 US US13/794,224 patent/US9228019B2/en active Active
-
2014
- 2014-12-26 JP JP2014263780A patent/JP6129152B2/ja active Active
-
2015
- 2015-02-05 PH PH12015500248A patent/PH12015500248A1/en unknown
- 2015-02-05 CR CR20150054A patent/CR20150054A/es unknown
- 2015-04-28 IL IL238505A patent/IL238505A/en active IP Right Grant
-
2016
- 2016-08-22 US US15/243,046 patent/US9815902B2/en active Active
-
2017
- 2017-03-06 JP JP2017041210A patent/JP2017123866A/ja active Pending
-
2018
- 2018-01-03 US US15/725,253 patent/US20180100019A1/en not_active Abandoned
- 2018-06-05 HR HRP20180873TT patent/HRP20180873T1/hr unknown
- 2018-06-06 CY CY181100591T patent/CY1120665T1/el unknown
- 2018-07-20 AR ARP180102046 patent/AR112564A2/es unknown
-
2021
- 2021-08-20 US US17/407,651 patent/US20220073629A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2698203C (fr) | Anticorps anti-cxcr5 humanises, leurs derives et leurs utilisations | |
AU2013203261B2 (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20130826 |